

  
**Perkins**



*Perkins Discovery Fund*

*Seeking Capital Appreciation through the Discovery of Emerging Companies*

**Semi-Annual Report to Shareholders**

**PERKINS DISCOVERY FUND**

**For the Six Months ended  
September 30, 2017  
(unaudited)**

October 30, 2017

Dear Shareholders:

The fiscal six-month period ended September 30, 2017 was very good for the Perkins Discovery Fund and micro-cap stocks in general. The Fund finished the period with a return of 18.92% versus 9.48% for the Wilshire Micro-Cap, 7.56% for the Russell 2000, 9.88% for the NASDAQ Composite and 6.63% for the S&P 500. Micro-cap stocks, overall, performed better than large-cap as represented by the S&P 500.

At the Perkins Discovery Fund, we follow a bottom-up approach, using both fundamental and technical chart analysis to find new investment opportunities one by one and to monitor our current holdings. During the six-month period, we acquired 3 new holdings and disposed of 5. As a result, the portfolio went from 22 holdings to 20. We started the period with 99.10% invested in equities and ended with 93.96% invested in equities.

Our three best gaining stocks for the six-month period were AxoGen, Inc., ePlus, Inc. and NeoGenomics, Inc. AxoGen, with a focus on peripheral nerve injuries, provides surgeons with solutions to repair and protect peripheral nerves and to measure and monitor nerve function. Purchased over two years ago, the stock has been a strong performer with year-over-year revenue growth exceeding 40% most quarters since our purchase. It was also a top performer for the Fund last year. ePlus enables organizations to optimize their IT infrastructure and supply chain processes by delivering world-class IT products from top manufacturers, professional services, flexible lease financing, proprietary software, and patented business methods and systems. We have owned the company since 2009 as the stock was breaking out in a multi-year base. The company has continued to perform very well and the stock is in a strong uptrend. Although we have sold part of our position along the way, it is still one of the Fund's largest holdings. NeoGenomics operates a network of CLIA-certified clinical laboratories that specialize in cancer genetics diagnostic testing, servicing the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. We purchased our position in late 2013 and it has been a steady performer. They are in the fastest growing segment of the laboratory industry.

The Fund's three worst declining stocks for the period were Depomed, Inc., US Physical Therapy, Inc. and Ooma, Inc. Depomed, Inc. is a specialty pharmaceutical company focused on products to treat pain and other central nervous system conditions. Known for successfully building brands, their acquisition of the U.S. rights for Nucynta from Johnson and Johnson's Janssen Pharmaceuticals provides them with another opportunity to build a major brand. Unfortunately, the macro environment for opioids has been negative over the last year and the stock is down, however, Nucynta has been gaining market share due to its better safety profile. US Physical Therapy is a pure-play operator of outpatient physical and occupational therapy clinics with 570 clinics in 41 states. Originally purchased in 2008, US Physical Therapy was a big winner for the Fund which we sold in August after it had broken down from a long-term uptrend. Ooma is a provider of cloud-based internet phone services to homes and small businesses. Following a disappointing first quarter, we sold our position which was a short-term holding.

The table below shows the Fund's performance for various periods ended September 30, 2017.

<b>Annualized Total Return</b>	<b>Perkins Discovery Fund</b>	<b>Wilshire US Micro-Cap Index</b>	<b>Russell 2000 Index</b>	<b>NASDAQ Composite Index</b>	<b>S&amp;P 500 Index</b>
<b>Since 4-9-98 Inception</b>	9.99%	7.93%	5.99%	6.75%	4.29%
<b>Fifteen Year</b>	10.04%	10.82%	9.89%	12.09%	7.81%
<b>Ten Year</b>	3.03%	5.87%	6.35%	9.17%	5.14%
<b>Five Year</b>	8.25%	12.20%	12.23%	15.83%	11.83%
<b>Three Year</b>	4.40%	9.27%	10.61%	13.07%	8.50%
<b>One Year</b>	13.52%	20.28%	19.11%	22.29%	16.19%

*Please note that performance data quoted represents past performance; past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance of the fund may be lower or higher than the performance quoted. Performance data current to the most recent month end may be obtained by calling 800-366-8361. The fund imposes a 1.00% redemption fee on shares held less than 45 days. Performance data does not reflect the redemption fee. If it had, the return would be reduced.*

After a pullback into last fall's election, the market has continued its previous rally. As we said earlier, small-and micro-cap stocks, in general, have outperformed large-caps during the period. This trend change comes after several years of underperformance and leads us to believe that small company stocks can continue to outpace the general market for the time being.


We cannot control the action of the market; however, we will continue to choose stocks that we believe can do well over the long term using our same bottom-up selection process of looking for small companies that are benefiting from positive change. And, of course, we continue to monitor our holdings. Some of these will reach levels where they will be sold, even though they may continue to be good companies. Others will not work out in the way we anticipated and will be candidates to be sold. Both will be replaced with new ideas, as part of an ongoing process. We believe the Discovery Fund is well positioned in micro-cap growth stocks that hold significant promise for the future.

Thank you for your continued support.

Sincerely,



Richard W. Perkins, C.F.A.  
President



Daniel S. Perkins, C.F.A.  
Executive Vice President

Opinions expressed above are those of Richard W. Perkins or Daniel S. Perkins and are subject to change, are not guaranteed and should not be considered recommendations to buy or sell any security.

**Small company investing involves additional risks such as limited liquidity and greater volatility. The fund invests in micro-cap and early stage companies which tend to be more volatile and somewhat more speculative than investments in more established companies. As a result, investors considering an investment in the Fund should consider their ability to withstand the volatility of the Fund's net asset value associated with the risks of the portfolio.**

The S&P 500 Index is a broad-based unmanaged index of 500 stocks, which is widely recognized as representative of the equity market in general; the Russell 2000 Index consists of the smallest 2,000 companies in a group of 3,000 U.S. companies in the Russell 3000 Index, as ranked by market capitalization; and the NASDAQ Composite Index is a market capitalization-weighted index that is designed to represent the performance of the National Market System, which includes over 5,000 stocks traded only over-the-counter and not on an exchange. The Dow Jones Wilshire Micro-Cap Index is formed by taking the 2,500 smallest companies, as measured by Market Capitalization of the Dow Jones Wilshire 5000 Index. One cannot invest directly in an index. Please refer to the schedule of investments for more information regarding fund holdings. Fund holdings are subject to change and are not recommendations to buy or sell any security.

Investment performance reflects fee waivers in effect. In the absence of such waivers, total return would be reduced.

Must be preceded or accompanied by a prospectus. Please read it carefully before investing.

The Fund is distributed by First Dominion Capital Corp. (11/17)


## **Important Disclosure Statement**

*The Fund's prospectus contains important information about the Fund's investment objectives, potential risks, management fees, charges and expenses, and other information and should be read and considered carefully before investing. The Fund's past performance does not guarantee future results. The investment return and principal value of an investment in the Fund will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. You may obtain a current copy of the Fund's prospectus by calling 1-800-673-0550. Distributed by First Dominion Capital Corp., Richmond, VA.*

*Current performance of the Fund may be lower or higher than the performance quoted. Performance data current to the most recent month end may be obtained by calling 1-800-673-0550. Information provided with respect to the Fund's Portfolio Holdings, Sector Weightings, Number of Holdings and Expense Ratios are as of September 30, 2017 and are subject to change at any time.*

*Stated performance in the Fund was achieved at some or all points during the period by Perkins Capital Management, Inc. ("Perkins"), the investment advisor to the Fund. Perkins waived or reimbursed part of the Fund's total expenses. Had Perkins not waived or reimbursed expenses of the Fund, the Fund's performance would have been lower.*

**PERKINS DISCOVERY FUND  
HOLDINGS BY INDUSTRY SECTOR  
AS PERCENTAGE OF NET ASSETS  
AS OF SEPTEMBER 30, 2017 (unaudited)**



**PERKINS DISCOVERY FUND**  
**SCHEDULE OF INVESTMENTS**  
**September 30, 2017**  
**(unaudited)**

	<u>Shares</u>	<u>Fair Value</u>
<b>COMMON STOCKS - 96.15%</b>		
<b>COMPUTER PROGRAMMING - 2.97%</b>		
USA Technologies, Inc.*	35,000	\$ <u>218,750</u>
<b>FOOD &amp; BEVERAGE MANUFACTURING - 2.86%</b>		
Craft Brew Alliance, Inc.*	12,000	<u>210,600</u>
<b>HEALTH CARE MANUFACTURING - 19.05%</b>		
AtriCure, Inc.*	25,000	559,250
Cardiovascular Systems, Inc.*	30,000	<u>844,500</u>
		<u>1,403,750</u>
<b>HEALTH CARE DRUGS/SERVICES - 15.24%</b>		
BioScrip, Inc.*	55,000	151,250
Depomed, Inc.*	25,000	144,750
NeoGenomics, Inc.*	50,000	556,500
Vericel Corp.*	45,000	<u>270,000</u>
		<u>1,122,500</u>
<b>HEALTH CARE SUPPLIES - 18.39%</b>		
Antares Pharma, Inc.*	40,000	129,600
AxoGen Corp.*	50,000	967,500
Cogentix Medical, Inc.*	55,000	140,800
IRIDEX Corp.*	12,500	<u>117,125</u>
		<u>1,355,025</u>
<b>HEALTH CARE SUPPORT - 12.53%</b>		
BioTelemetry, Inc.*	15,000	495,000
Rockwell Medical, Inc.*	50,000	<u>428,000</u>
		<u>923,000</u>
<b>OIL &amp; GAS - 7.22%</b>		
Ring Energy, Inc.*	10,000	144,900
SRC Energy, Inc.*	40,000	<u>386,800</u>
		<u>531,700</u>

**PERKINS DISCOVERY FUND**  
**SCHEDULE OF INVESTMENTS - continued**  
**September 30, 2017**  
**(unaudited)**

	<u>Shares</u>	<u>Fair Value</u>
<b>POLLUTION CONTROL EQUIPMENT - 0.50%</b>		
LiqTech International, Inc.*	100,000	\$ 37,000
<b>SOFTWARE SERVICES - 17.39%</b>		
Digital Turbine, Inc.*	50,000	75,500
ePlus, Inc.*	10,000	924,500
InnerWorkings, Inc.*	25,000	281,250
		<u>1,281,250</u>
<b>TOTAL COMMON STOCKS - 96.15%</b>		
<b>(Cost: \$3,087,543)</b>		<u>7,083,575</u>
<b>SHORT TERM INVESTMENT - 6.18%</b>		
Fidelity Investments Money Market Fund 0.92%		
(Cost: \$455,054)	455,054	455,054
<b>TOTAL INVESTMENTS - 102.33%</b>		
<b>(Cost: \$3,542,597)</b>		7,538,629
<b>Liabilities, in excess of other assets - (2.33)%</b>		<u>(171,278)</u>
<b>NET ASSETS - 100.00%</b>		<u><u>\$7,367,351</u></u>

\*Non-Income producing.

\*\*Effective 7 day yield as of September 30, 2017.

See Notes to Financial Statements

**PERKINS DISCOVERY FUND**  
**STATEMENT OF ASSETS AND LIABILITIES**  
**September 30, 2017 (unaudited)**

---

**ASSETS**

Investments at fair value (identified cost of \$3,542,597) (Note 1)	\$7,538,629
Receivable for capital stock sold	58
Dividends and interest receivable	369
Prepaid expenses	11,595
<b>TOTAL ASSETS</b>	<u>7,550,651</u>

**LIABILITIES**

Payable for capital stock purchased	10,226
Payable for securities purchased	144,463
Accrued advisory fees	455
Accrued 12b-1 fees	9,971
Accrued administration, transfer agent and accounting fees	5,646
Accrued professional fees	10,405
Other accrued expenses	2,134
<b>TOTAL LIABILITIES</b>	<u>183,300</u>

**NET ASSETS** \$7,367,351

**Net Assets Consist of:**

Paid-in-capital	\$4,057,174
Accumulated undistributed net investment income (loss)	(121,761)
Accumulated net realized gain (loss) on investments	(564,094)
Net unrealized appreciation (depreciation) of investments	3,996,032

**Net Assets** \$7,367,351

**NET ASSET VALUE PER SHARE**

**Investor Class Shares:**

Net Assets	\$7,367,351
Shares Outstanding (unlimited number of shares of beneficial interest authorized without par value)	185,528
Net Asset Value and Offering Price Per Share	<u>\$ 39.71</u>
Redemption Price Per Share *	<u>\$ 39.31</u>

\*Redemption Price includes fee of 1% per share on the proceeds redeemed within 45 days of purchase.

See Notes to Financial Statements

**PERKINS DISCOVERY FUND**  
**STATEMENT OF OPERATIONS**  
**Six months ended September 30, 2017 (unaudited)**

---

**INVESTMENT INCOME**

Dividend	\$ 3,750
Interest	1,603
Total investment income	<u>5,353</u>

**EXPENSES**

Investment management fees (Note 2)	34,461
12b-1 fees (Note 2)	8,615
Recordkeeping and administrative services (Note 2)	8,009
Accounting fees (Note 2)	10,702
Custody fees	1,657
Transfer agent fees (Note 2)	7,864
Professional fees	18,502
Filing and registration fees	7,412
Trustee fees	2,437
Compliance fees	3,738
Shareholder reports	4,295
Shareholder servicing	1,195
Insurance	1,543
Other	4,627
Total expenses	<u>115,057</u>
Management fee waivers (Note 2)	<u>(28,904)</u>
Net Expenses	<u>86,153</u>
Net investment income (loss)	<u>(80,800)</u>

**REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMENTS**

Net realized gain (loss) on investments	361,095
Net increase (decrease) in unrealized appreciation (depreciation) of investments	<u>913,972</u>
Net realized and unrealized gain (loss) on investments	<u>1,275,067</u>

**INCREASE (DECREASE) IN NET ASSETS FROM OPERATIONS** \$1,194,267

See Notes to Financial Statements

**PERKINS DISCOVERY FUND**  
**STATEMENTS OF CHANGES IN NET ASSETS**

	<b>Six months ended September 30, 2017 (unaudited)</b>	<b>Year ended March 31, 2017</b>
<b>Increase (decrease) in Net Assets</b>		
<b>OPERATIONS</b>		
Net investment income (loss)	\$ (80,800)	\$ (157,858)
Net realized gain (loss) on investments	361,095	633,153
Net increase (decrease) in unrealized appreciation (depreciation) of investments	913,972	811,093
Increase (decrease) in net assets from operations	<u>1,194,267</u>	<u>1,286,388</u>
<b>CAPITAL STOCK TRANSACTIONS (NOTE 5)</b>		
Shares sold	46,332	382,559
Shares redeemed	<u>(314,390)</u>	<u>(1,405,514)</u>
Increase (decrease) in net assets from capital stock transactions	<u>(268,058)</u>	<u>(1,022,955)</u>
<b>NET ASSETS</b>		
Increase (decrease) during period	926,209	263,433
Beginning of period	<u>6,441,142</u>	<u>6,177,709</u>
End of period*	<u>\$7,367,351</u>	<u>\$6,441,142</u>
* Includes undistributed net investment income (loss) of:	<u>\$ (121,761)</u>	<u>\$ (40,961)</u>

See Notes to Financial Statements

**PERKINS DISCOVERY FUND**  
**FINANCIAL HIGHLIGHTS**  
**SELECTED PER SHARE DATA THROUGHOUT EACH PERIOD**

	Six months ended					
	September 30, 2017	Year Ended March 31,				
	(unaudited)	2017	2016	2015	2014	2013
<b>Net asset value, beginning of period</b>	\$ 33.39	\$ 27.52	\$ 37.54	\$ 38.98	\$ 30.23	\$ 25.99
<b>Investment activities</b>						
Net investment income (loss) <sup>(1)</sup>	(0.42)	(0.75)	(0.67)	(0.71)	(0.62)	(0.34)
Net realized and unrealized gain (loss) on investments	6.74	6.62	(9.35)	(0.73)	9.37	4.98
<b>Total from investment activities</b>	<b>6.32</b>	<b>5.87</b>	<b>(10.02)</b>	<b>(1.44)</b>	<b>8.75</b>	<b>4.64</b>
<b>Distributions</b>						
Net investment income	-	-	-	-	-	(0.40)
<b>Total distributions</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(0.40)</b>
Paid-in capital from redemption fees	-	-	-( <sup>2</sup> )	-	-	-
<b>Net asset value, end of period</b>	<b>\$ 39.71</b>	<b>\$ 33.39</b>	<b>\$ 27.52</b>	<b>\$ 37.54</b>	<b>\$ 38.98</b>	<b>\$ 30.23</b>
<b>Total Return</b>	<b>18.93%**</b>	<b>21.33%</b>	<b>(26.69%)</b>	<b>(3.69%)</b>	<b>28.94%</b>	<b>18.10%</b>
<b>Ratios/Supplemental Data</b>						
Ratio to average net assets						
Expenses, gross	3.34%*	3.31%	3.27%	2.84%	2.83%	3.18%
Expenses, net of waiver (Note 2)	2.50%*	2.42%	2.25%	2.16%	2.00%	2.00%
Net investment income (loss)	(2.34%)*	(2.29%)	(2.01%)	(1.96%)	(1.81%)	(1.30%)
Portfolio turnover rate	6.27%**	17.80%	2.20%	21.13%	23.98%	12.97%
Net assets, end of period (000's)	\$ 7,367	\$ 6,441	\$ 6,178	\$ 9,619	\$ 12,602	\$ 10,491

<sup>(1)</sup> Per share amounts calculated using the average shares outstanding the period.

<sup>(2)</sup> Less than \$0.01 per share.

\* Annualized

\*\* Not annualized

See Notes to Financial Statements

## **NOTE 1 – ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES**

The Perkins Discovery Fund (the “Fund”) is a diversified series of the World Funds Trust (“WFT”), which is registered under The Investment Company Act of 1940, as amended, as an open-end management company. WFT was organized as a Delaware statutory trust on April 9, 2007. The Fund was established on April 9, 1998 as a series of Professionally Managed Portfolios. On October 26, 2012, the Fund reorganized as a separate series of WFT.

The Fund’s objective is to seek long-term capital appreciation.

The following is a summary of significant accounting policies consistently followed by the Fund. The policies are in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The Fund follows the investment company accounting and reporting guidance of the Financial Accounting Standards Board (“FASB”) Accounting Standard Codification Topic 946 “Financial Services – Investment Companies”.

### **Security Valuation**

The Fund’s securities are valued at current market prices. Investments in securities traded on the national securities exchanges or included in the NASDAQ National Market System are valued at the last reported sale price. Other securities traded in the over-the-counter market and listed securities for which no sales are reported on a given date are valued at the last reported bid price. Short-term debt securities (less than 60 days to maturity) are valued at their fair value using amortized cost. Other assets for which market prices are not readily available are valued at their fair value as determined in good faith under procedures set by the Board. Generally, trading in corporate bonds, U.S. government securities and money market instruments is substantially completed each day at various times before the scheduled close of the NYSE. The value of these securities used in computing the NAV is determined as of such times.

The Fund has a policy that contemplates the use of fair value pricing to determine the net asset value (“NAV”) per share of the Fund when market prices are unavailable as well as under special circumstances, such as: (i) if the primary market for a portfolio security suspends or limits trading or price movements of the security; and (ii) when an event occurs after the close of the exchange on which a portfolio security is principally traded that is likely to have changed the value of the security. Since most of the Fund’s investments are traded on U.S. securities exchanges, it is anticipated that the use of fair value pricing will be limited.

When the Fund uses fair value pricing to determine the NAV per share of the Fund, securities will not be priced on the basis of quotations from the primary market in which they are traded, but rather may be priced by another method that the Board

**PERKINS DISCOVERY FUND**  
**NOTES TO FINANCIAL STATEMENTS - continued**  
**September 30, 2017 (unaudited)**

---

believes accurately reflects fair value. Any method used will be approved by the Board and results will be monitored to evaluate accuracy. The Fund's policy is intended to result in a calculation of the Fund's NAV that fairly reflects security values as of the time of pricing. However, fair values determined pursuant to the Fund's procedures may not accurately reflect the price that the Fund could obtain for a security if it were to dispose of that security as of the time of pricing.

The Fund has adopted fair valuation accounting standards that establish an authoritative definition of fair value and set out a hierarchy for measuring fair value. These standards require additional disclosures about the various inputs used to develop the measurements of fair value. These inputs are summarized in the three broad levels listed below.

Various inputs are used in determining the value of a Fund's investments. GAAP established a three-tier hierarchy of inputs to establish a classification of fair value measurements for disclosure purposes. Level 1 includes quoted prices in active markets for identical securities. Level 2 includes other significant observable market-based inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). Level 3 includes significant unobservable inputs (including the Fund's own assumptions in determining fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund's investments as of September 30, 2017:

	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
	<b>Quoted</b>	<b>Other</b>	<b>Significant</b>	
	<b>Prices</b>	<b>Significant</b>	<b>Unobservable</b>	
	<u>Prices</u>	<u>Observable</u>	<u>Inputs</u>	<u>Total</u>
	<u>Inputs</u>	<u>Inputs</u>	<u>Inputs</u>	<u>Total</u>
Common Stocks	\$7,083,575	\$-	\$-	\$7,083,575
Short term Investments	455,054	-	-	455,054
	<u>\$7,538,629</u>	<u>\$-</u>	<u>\$-</u>	<u>\$7,538,629</u>

Refer to the Fund's Schedule of Investments for a listing of the securities by type and industry.

There were no transfers into or out of any levels during the six months ended September 30, 2017. The Fund recognizes transfers between fair value hierarchy levels at the end of the reporting period. The Fund held no Level 3 securities at any time during the year ended September 30, 2017.

### **Security Transactions and Income**

Security transactions are accounted for on the trade date. The cost of securities sold is determined generally on specific identification basis. Realized gains and losses from security transactions are determined on the basis of identified cost for book and tax purposes. Dividends are recorded on the ex-dividend date. Interest income is recorded on an accrual basis.

### **Cash and Cash Equivalents**

Cash and cash equivalents consist of overnight deposits with the custodian bank which earn interest at the current market rate.

### **Accounting Estimates**

In preparing financial statements in conformity with GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

### **Federal Income Taxes**

The Fund intends to comply with the requirements of the Internal Revenue Code applicable to regulated investment companies and to distribute all of its taxable income to its shareholders. The Fund also intends to distribute sufficient net investment income and net capital gains, if any, so that it will not be subject to excise tax on undistributed income and gains. Therefore, no federal income tax or excise provision is required.

Management has reviewed the Fund's tax positions for each of the open tax years (2015-2017) or expected to be taken in the Fund's 2018 tax returns and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken in the Fund's tax returns. The Fund has no examinations in progress and management is not aware of any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly change.

### **Reclassification of Capital Accounts**

GAAP requires that certain components of net assets relating to permanent differences be reclassified between financial and tax reporting. For the six months ended September 30, 2017, there were no such classifications.

**PERKINS DISCOVERY FUND**  
**NOTES TO FINANCIAL STATEMENTS - continued**  
**September 30, 2017 (unaudited)**

---

**NOTE 2 - INVESTMENT ADVISORY AND DISTRIBUTION AGREEMENTS  
AND OTHER TRANSACTIONS WITH AFFILIATES**

Pursuant to an Investment Advisory Agreement, the Advisor, Perkins Capital Management, Inc. ("Perkins") provides investment services for an annual fee of 1.00% of average daily net assets of the Fund.

Perkins received and waived investment management fees and reimbursed expenses for the six months ended September 30, 2017 as follows:

<u>Fee Earned</u>	<u>Fee Waived</u>	<u>Expenses Reimbursed</u>
\$34,461	\$28,904	\$-

Perkins has contractually agreed to reduce its fees and/or pay Fund expenses (excluding interest, expenses incurred under a plan of distribution adopted pursuant to Rule 12b-1 under the 1940 Act, taxes, acquired fund fees and expenses, brokerage commissions, dividend expenses on short sales and other expenditures which are capitalized in accordance with GAAP, other extraordinary expenses not incurred in the ordinary course of such Fund's business,) in order to limit Total Annual Fund Operating Expenses After Fee Waiver and/or Expense Reimbursement for shares of the Fund to 2.25% of the Fund's average net assets (the "Expense Cap"). The Expense Cap will remain in effect until at least July 31, 2018. The Agreement may be terminated at any time by the Board upon 60 days' notice to Perkins, or by Perkins with the consent of the Board. Each waiver or reimbursement of an expense by Perkins is subject to repayment by the Fund within the three fiscal years following the fiscal year in which the expense was incurred, provided that the Fund is able to make the repayment without exceeding the expense limitation in place at the time of the waiver or reimbursement and at the time the waiver or reimbursement is recouped.

The total amount of recoverable reimbursements for the Fund as of September 30, 2017, and expiration dates was as follows:

<u>Recoverable Reimbursements and Expiration Dates</u>				
<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>	<u>Total</u>
\$72,133	\$81,786	\$61,169	\$28,904	\$243,992

The Fund has adopted a Distribution Plan (the "Plan") in accordance with Rule 12b-1 under the 1940 Act, providing for the payment of distribution and service fees to Perkins as Distribution Coordinator of the Fund. The Plan provides that the Fund may pay a fee to Perkins at an annual rate of up to 0.25% of average daily net assets of the Fund in consideration for distribution related services.

The Fund has adopted a shareholder service plan. Under a shareholder services plan, the Fund may pay an authorized firm up to 0.25% on an annualized basis of average daily net assets attributable to its customers who are shareholders. For this fee, the

**PERKINS DISCOVERY FUND**  
**NOTES TO FINANCIAL STATEMENTS – continued**  
**September 30, 2017 (unaudited)**

---

authorized firms may provide a variety of services, such as: 1) receiving and processing shareholder orders; 2) performing the accounting for the shareholder’s account; 3) maintaining retirement plan accounts; 4) answering questions and handling correspondence for individual accounts; 5) acting as the sole shareholder of record for individual shareholders; 6) issuing shareholder reports and transaction confirmations; 7) executing daily investment “sweep” functions; and 8) furnishing investment advisory services.

For the six months ended September 30, 2017, the following expenses were incurred:

<u>Class</u>	<u>Type of Plan</u>	<u>Fees Incurred</u>
Investor	12b-1	\$8,615
Investor	Shareholder Services	\$1,195

First Dominion Capital Corp. (“FDCC”) acts as the Fund’s principal underwriter and distributor in the continuous public offering of the Fund’s shares. For the six months ended September 30, 2017, FDCC received no commissions or underwriting fees from the sale of the Fund’s shares.

Commonwealth Fund Services, Inc. (“CFS”), acts as the Fund’s administrator, transfer and dividend disbursing agent and accounting agent. As administrator, CFS provides shareholder, recordkeeping, administrative and blue-sky filing services. For the six months ended September 30, 2017, the following fees were earned:

<u>Record Keeping &amp; Administration</u>	<u>Transfer Agent</u>	<u>Accounting Agent</u>
\$8,009	\$7,864	\$10,702

Certain officers of the Trust are also officers and/or directors of FDCC and CFS. Additionally, John H. Lively of the Law Offices of John H. Lively and Associates, Inc., a member of The 1940 Act Law Group™, serves as legal counsel to the Trust. John H. Lively, Secretary of the Trust, is the owner of the Law Offices of John H. Lively and Associates, Inc. Mr. Lively receives no special compensation from the Trust or the Fund for serving as an officer of the Trust.

**NOTE 3 – INVESTMENTS**

The cost of purchases and proceeds from the sales of securities other than short-term notes for the six months ended September 30, 2017, were as follows

<u>Purchases</u>	<u>Sales</u>
\$413,879	\$997,696

**NOTE 4 - DISTRIBUTIONS TO SHAREHOLDERS AND TAX COMPONENTS OF CAPITAL**

Distributions are determined on a tax basis and may differ from net investment income and realized capital gains for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statements to reflect their tax character. Temporary differences arise when certain items of income, expense, gain or loss are recognized in different periods for financial statement and tax purposes; these differences will reverse at some time in the future. Differences in classification may also result from the treatment of short-term gains as ordinary income for tax purposes.

During the six months ended September 30, 2017 and the year ended March 31, 2017, no distributions were paid.

As of September 30, 2017, the components of distributable earnings (accumulated loss) on a tax basis were as follows:

Accumulated undistributed net investment loss	\$ (121,761)
Accumulated net realized gain (loss)	(564,094)
Net unrealized appreciation (depreciation) on investments	3,996,032
	<u>\$3,310,177</u>

Under the Regulated Investment Company Modernization Act of 2010 ("2010 Act"), net capital losses recognized after December 31, 2010, may be carried forward indefinitely, and their character is retained as short-term and/or long-term losses. Under the laws in effect prior to the 2010 Act, pre-enactment net capital losses were carried forward for eight years and treated as short-term losses. As a transition rule, the 2010 Act requires that post-enactment net capital losses be used before pre-enactment net capital losses. As of March 31, 2017, the Fund has a capital loss carryforward of \$925,189 available to offset future capital gains. \$860,612 of the loss carryforward expires in 2018 and \$64,577 of short-term can be carried forward indefinitely.

Cost of securities for Federal Income tax purpose and the related tax-based net unrealized appreciation (depreciation) consists of:

<u>Cost</u>	<u>Gross Unrealized Appreciation</u>	<u>Gross Unrealized Depreciation</u>	<u>Total Unrealized Appreciation (Depreciation)</u>
\$3,542,597	\$4,281,145	\$(285,113)	\$3,996,032

PERKINS DISCOVERY FUND  
NOTES TO FINANCIAL STATEMENTS - continued  
September 30, 2017 (unaudited)

---

**NOTE 5 - TRANSACTIONS IN SHARES OF BENEFICIAL INTEREST**

Shares of beneficial interest transactions for the Fund were:

	<b>Six months ended September 30, 2017 (unaudited)</b>	<b>Year ended March 31, 2017</b>
Shares sold	1,283	11,570
Shares redeemed	<u>(8,640)</u>	<u>(43,174)</u>
Net increase (decrease)	<u>(7,357)</u>	<u>(31,604)</u>

**NOTE 6 - SUBSEQUENT EVENTS**

Management has evaluated all transactions and events subsequent to the date of the statement of assets and liabilities through the date on which these financial statements were issued. Except as already included in the notes to these financial statements, no additional items require disclosure.

## **VOTING PROXIES ON FUND PORTFOLIO SECURITIES**

A description of the policies and procedures that the Fund uses to determine how to vote proxies relating to securities held in the Fund's portfolio is available, without charge and upon request, by calling 1-800-637-0550 or on the SEC's website at [www.sec.gov](http://www.sec.gov). Information regarding how the Fund voted proxies relating to portfolio securities during the most recent twelve months ended June 30 is available on or through the SEC's website at [www.sec.gov](http://www.sec.gov).

## **QUARTERLY PORTFOLIO HOLDINGS**

The Fund files with the SEC a complete schedule of its portfolio holdings, as of the close of the first and third quarters of its fiscal year, on "Form N-Q". These filings are available, without charge and upon request, by calling 1-800-637-0550 or on the SEC's website at [www.sec.gov](http://www.sec.gov). The Fund's Forms N-Q may be reviewed and copied at the SEC's Public Reference Room in Washington, D.C. Information on the operation of the Public Reference Room may be obtained by calling 1-800-SEC-0330.

**PERKINS DISCOVERY FUND**  
**FUND EXPENSES (unaudited)**

---

**Fund Expenses Example**

As a shareholder of the Fund, you incur two types of costs: (1) transaction costs, including redemption fees and (2) ongoing costs, including management fees, distribution (12b-1) fees, and other Fund expenses. This example is intended to help you understand your ongoing costs (in dollars) of investing in the Fund and to compare these costs with the ongoing costs of investing in other mutual funds. The example is based on an investment of \$1,000 invested at the beginning of the period, April 1, 2017 and held for the six months ended September 30, 2017.

**Actual Expenses Example**

The first line of the table below provides information about actual account values and actual expenses. You may use the information in this line, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by \$1,000 (for example, an \$8,600 account value divided by \$1,000= 8.6), then multiply the result by the number in the first line under the heading entitled "Expenses Paid During the Period" to estimate the expenses you paid on your account during this period.

**Hypothetical Example for Comparison Purposes**

The second line of the table below provides information about hypothetical account values and hypothetical expenses based on the Fund's actual expense ratio and an assumed rate of return of 5% per year before expenses, which is not the Fund's actual return. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in the Fund and other funds. To do so, compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of the other funds.

Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transactional costs, such as sales charges (loads). Therefore, the second line of the table is useful in comparing ongoing costs only, and will not help you determine the relative total costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.

	<b>Beginning Account Value 4/1/2017</b>	<b>Ending Account Value 9/30/2017</b>	<b>Annualized Expense Ratio</b>	<b>Expenses Paid During Period Ended* 9/30/2017</b>
Investor Class Actual	\$1,000	\$1,189.28	2.50%	\$13.72
Investor Class Hypothetical**	\$1,000	\$1,012.50	2.50%	\$12.61

\* Expenses are equal to the Fund's annualized expense ratio, multiplied by the average account value for the period, multiplied by 183 days in the most recent fiscal half year divided by 365 days in the current year.

\*\* 5% return before expenses.





**Investment Adviser:**

Perkins Capital Management, Inc.  
730 East Lake Street  
Wayzata, MN 55391-1769

**Distributor:**

First Dominion Capital Corp.  
8730 Stony Point Parkway, Suite 205  
Richmond, VA 23235

**Independent Registered Public Accounting Firm:**

Tait, Weller & Baker LLP  
1818 Market Street, Suite 2400  
Philadelphia, PA 19103

**Transfer Agent, Fund Accounting and Fund Administration:**

Commonwealth Fund Services, Inc.  
8730 Stony Point Parkway, Suite 205  
Richmond, VA 23235

**Legal Counsel:**

The Law Offices of John H. Lively & Associates, Inc.  
A member firm of The 1940 Act Law Group™  
11300 Tomahawk Creek Parkway, Suite 310  
Leawood, KS 66211

**More Information:**

For 24 hours, 7 days a week price information, and for information on any series of the World Funds Trust investment plans, and other shareholder services, call Commonwealth Fund Services, Inc. Toll Free at (800) 673-0550.